S P Khor

Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.

Sharyn D. Baker, S P Khor, Alex A. Adjei et al. · Journal of Clinical Oncology · 1996 · 138 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.

Richard L. Schilsky, John Hohneker, Mark J. Ratain et al. · Journal of Clinical Oncology · 1998 · 105 citations

Medicine, Oncology, Pharmacology +17

Pharmacokinetics of RheothRx Injection in Healthy Male Volunteers

Roxanne C. Jewell, S P Khor, David F. Kisor et al. · Journal of Pharmaceutical Sciences · 1997 · 64 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +4

Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. II. Distribution of phencyclidine in the rat.

S P Khor, Haig Bozigian, Michael Mayersohn · Drug Metabolism and Disposition · 1991 · 55 citations

Pharmacy, Pharmacokinetics, Pharmacology +10

5-Ethynyluracil (776C85), a modulator of the therapeutic activity of 5-fluorouracil

T Spector, David Porter, Donald J. Nelson et al. · Drugs of the Future · 1994 · 45 citations

Medicine, Pharmacology, Pharmacotherapy +6